SPECIALTY GUIDELINE MANAGEMENT

LYFGENIA (lovotibeglogene autotemcel)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Lyfgenia is indicated for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events.

Limitations of Use:

Following treatment with Lyfgenia, patients with α-thalassemia trait (-α3.7/-α3.7) may experience anemia with erythroid dysplasia that may require chronic red blood cell transfusions. Lyfgenia has not been studied in patients with more than two α-globin gene deletions.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

- A. Molecular or genetic testing results documenting sickle cell disease genotype
- B. Chart notes or medical records documenting history of severe vaso-occlusive episodes

III. PRESCRIBER SPECIALTIES

This medication must be prescribed by or in consultation with a hematologist.

IV. CRITERIA FOR INITIAL APPROVAL

Sickle Cell Disease

Authorization of one dose total may be granted for sickle cell disease when all of the following criteria are met:

- A. Member is 12 years of age or older.
- B. Member has a diagnosis of sickle cell disease with one of the following genotypes confirmed by molecular or genetic testing:
 - βs/βs
 - 2. βs/β⁰
 - 3. βs/β+
- C. Member has a documented history of at least 2 severe vaso-occlusive episodes per year during the previous two years (see Appendix for examples).
- D. Member is eligible for a hematopoietic stem cell transplant (HSCT) but is unable to find a human leukocyte antigen (HLA)-matched related donor.

Lyfgenia 6292-A SGM P2024.docx

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



6292-A

- E. Member has not received a prior hematopoietic stem cell transplant (HSCT).
- F. Member has not received Lyfgenia or any other gene therapy previously.
- G. Member does not have more than two α -globin gene deletions.


V. APPENDIX

Examples of Severe Vaso-Occlusive Events

- 1. Acute pain event requiring a visit to a medical facility and administration of pain medications (opioids or intravenous [IV] non-steroidal anti-inflammatory drugs [NSAIDs]) or RBC transfusions
- 2. Acute chest syndrome
- 3. Priapism lasting > 2 hours and requiring a visit to a medical facility
- 4. Splenic sequestration
- 5. Hepatic sequestration

VI. REFERENCES

- 1. Lyfgenia [package insert]. Somerville, MA: bluebird bio, Inc.; December 2023.
- 2. Walters JK, Krishnamurti L, Mapara MY, et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. NEJM. 2022;386(7):617-628.
- 3. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. National Institutes of Health. Available at https://www.nhlbi.nih.gov/sites/default/files/media/docs/sickle-cell-disease-report%20020816_0.pdf. Accessed December 13, 2023.



© 2024 CVS Caremark. All rights reserved.

